Evidence map›Paper›PMID 38937272›Full record

ArticleJournal of the National Cancer Institute2024

Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers.

Steven A Narod, Jacek Gronwald, Beth Karlan, Pal Moller, Tomasz Huzarski, Nadine Tung, Amber Aeilts, Andrea Eisen, Susan Randall Armel, Christian F Singer and 11 more

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Ovarian cancer.Nature reviews. Disease primers · 2026
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Steven A NarodWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.ORCID 0000-0001-5798-0626
Jacek GronwaldInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Beth KarlanDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Pal MollerInherited Cancer Research Group, The Norwegian Radium Hospital, Department for Medical Genetics; and Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital; Oslo University Hospital, Oslo, Norway.
Tomasz HuzarskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Nadine TungBeth Israel Deaconess Medical Center, Boston, MA, USA.
Amber AeiltsDivision of Human Genetics, The Ohio State University Medical Center, Comprehensive Cancer Center, Columbus, OH, USA.
Andrea EisenToronto-Sunnybrook Regional Cancer Center, Toronto, ON, Canada.
Susan Randall ArmelPrincess Margaret Cancer Centre, University of Toronto, ON, Canada.
Christian F SingerDepartment of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
William D FoulkesProgram in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montréal, QC, Canada.ORCID 0000-0001-7427-4651
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Olufunmilayo OlopadeDepartment of Medicine and Human Genetics, University of Chicago, Chicago, IL, USA.
Tuya PalUniversity Medical Center/Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.
Robert FruscioDepartment of Medicine and Surgery, University of Milan Bicocca, IRCCS San Gerardo, Monza, Italy.
Kelly MetcalfeWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Rebecca RajWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Michelle JacobsonWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Ping SunWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Jan LubinskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Joanne KotsopoulosWomen's College Research Institute, Women's College Hospital, Toronto, ON, Canada.ORCID 0000-0001-9624-4218

Funding

Canada Research ChairCanadian Cancer SocietyCanadian Cancer Society Research Institute 703058CIHR FDN 154275Peter Gilgan Centre for Women's Cancers at Women's College Hospital
6 · The paper itself

Abstract

backgroundTo estimate the incidence of primary peritoneal cancer after preventive bilateral oophorectomy in women with a BRCA1 or BRCA2 mutation.

methodsA total of 6310 women with a BRCA1 or BRCA2 mutation who underwent a preventive bilateral oophorectomy were followed for a mean of 7.8 years from oophorectomy. The 20-year cumulative incidence of peritoneal cancer post-oophorectomy was estimated using the Kaplan-Meier method. A left-truncated Cox proportional hazards analysis was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) associated with the age at oophorectomy, year of oophorectomy, and family history of ovarian cancer as well as hormonal and reproductive risk factors.

resultsFifty-five women developed primary peritoneal cancer (n = 45 in BRCA1, 8 in BRCA2, and 2 in women with a mutation in both genes). Their mean age at oophorectomy was 48.9 years. The annual risk of peritoneal cancer was 0.14% for women with a BRCA1 mutation and 0.06% for women with a BRCA2 mutation. The 20-year cumulative risk of peritoneal cancer from the date of oophorectomy was 2.7% for BRCA1 carriers and 0.9% for BRCA2 mutation carriers. There were no peritoneal cancers in BRCA1 carriers who had the operation before age 35 or in BRCA2 carriers who had the operation before age 45.

conclusionsFor BRCA1 mutation carriers, the annual risk of peritoneal cancer for 20 years post-oophorectomy is 0.14% per year. The risk is lower for BRCA2 carriers (0.06% per year).

Indexed as

MutationOvarian NeoplasmsOvariectomyPeritoneal NeoplasmsAdultAgedBRCA1 ProteinBRCA2 ProteinFemaleGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseHeterozygoteHumansIncidenceKaplan-Meier EstimateBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Identifiers

PMID38937272
PMCPMC11542982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.